New echo study raises questions; aspirin often added to warfarin in AF without CAD, despite bleeding risk; two types of pulmonary hypertension respond to novel agent; diovan data-manipulation scandal in Japan
(Source: Radio TheHeart.org)
Source: Radio TheHeart.org - July 29, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
New echo study raises questions; aspirin often added to warfarin in AF without CAD, despite bleeding risk; two types of pulmonary hypertension respond to novel agent; Diovan data-manipulation scandal in Japan
New echo study raises questions; aspirin often added to warfarin in AF without CAD, despite bleeding risk; two types of pulmonary hypertension respond to novel agent; diovan data-manipulation scandal in Japan (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - July 29, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#182: ACC 2013: Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks; PREVAIL yanked from ACC program; Watchman device meets safety end point; Niacin full results in HPS2-THRIVE; Another strike for digoxin in AF
ACC 2013: Stopping rivaroxaban and warfarin temporarily in AF patients yields similar risks; PREVAIL yanked from ACC program; Watchman device meets safety end point; Niacin full results in HPS2-THRIVE; Another strike for digoxin in AF (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 13, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#181: What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS
What's going to be hot at ACC 2013; rivaroxaban STEMI study hits print as FDA delivers setback; Watchman ups quality of life vs chronic warfarin in nonvalvular AF; FDA again seeks more info on rivaroxaban in ACS (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 7, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
Bleeding Risk in Afib? Don't Fear Warfarin
This F1000 commentary reports on a study whose findings support the use of antithrombotic therapy in treating patients with atrial fibrillation. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - February 1, 2013 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
#170: SCAI releases new consensus on "ad hoc" PCI; societies prepare interventionalists for new payment codes; heart-healthy diet additive to drug benefits in secondary prevention; increased mortality with digoxin in AF; warfarin for six months should be
SCAI releases new consensus on "ad hoc" PCI; societies prepare interventionalists for new payment codes; heart-healthy diet additive to drug benefits in secondary prevention; increased mortality with digoxin in AF; warfarin for six months should be (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - December 14, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#169: Pall cast on Durata ICD lead as FDA document made public; "holistic" analysis shows domino effect of TAVI risk factors; CT coronary angiography identifies significant plaques in "normal" arteries; major bleeds with warfarin in AF are often fatal;
Pall cast on Durata ICD lead as FDA document made public; "holistic" analysis shows domino effect of TAVI risk factors; CT coronary angiography identifies significant plaques in "normal" arteries; major bleeds with warfarin in AF are often fatal; low seru (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - November 30, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#162: Beta blockers of no use in stable CAD; docs debate valve choice; Montreal cardiologist suspended; adherence to warfarin-adjustment algorithm sharpens anticoagulation: RE-LY; CV risk prediction: CRP, fibrinogen add modestly
Beta blockers of no use in stable CAD; docs debate valve choice; Montreal cardiologist suspended; adherence to warfarin-adjustment algorithm sharpens anticoagulation: RE-LY; CV risk prediction: CRP, fibrinogen add modestly (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - October 12, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#10: Novel anticoagulants in AF: An overview of the latest data with Dr Robert McBane
The past year has brought an embarrassment of riches in the realm of anticoagulation for patients with atrial fibrillation, as dabigatran, rivaroxaban, and apixaban vie to compete with warfarin. (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - July 11, 2012 Category: Cardiology Authors: theheart.org Tags: Mayo Clinic Talks Source Type: podcasts
#48: Focus on novel anticoagulants in clinical practice with Dr Elaine Hylek
Cardiologists now have a wealth of choice for anticoagulation, but with competitors to warfarin crowding the physician's office, it's increasingly difficult to select the most appropriate agent for patients with atrial fibrillation. (Source: The Bob Harrington Show)
Source: The Bob Harrington Show - May 25, 2012 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
#48: Focus on novel anticoagulants in clinical practice with Dr Elaine Hylek
Cardiologists now have a wealth of choice for anticoagulation, but with competitors to warfarin crowding the physician's office, it's increasingly difficult to select the most appropriate agent for patients with atrial fibrillation. (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - May 25, 2012 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
#140: Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate
Ideal blood-pressure goals? "We have no idea"; more adverse events seen on dabigatran vs warfarin; WHF defends Dubai WCC, reimburses Israelis denied visas; Roche stops dalcetrapib trial; bypass moderate coronary lesions? taking sides in the debate (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - May 11, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
